Feb. 3 at 9:58 PM
$AVXL The REALITY for bothe the EMA and FDA…okay ROW too..
If you don’t approve blarcamesine, Alzheimer’s care will stay focused on symptomatic treatments, early detection, lifestyle interventions, and the limited DMTs available, with no major near-term shift from infusion-based therapies.
Blarcamesine’s non-approval would delay diversification of oral, mechanism-specific options that target non-amyloid pathways, enhance convenience, improve access, minimize ARIA risks, and complement existing treatments.
You are not just regulators evaluating data—you are guardians of human suffering. Every day without this option means more stolen moments, more caregiver exhaustion, more despair for families clinging to any ray of hope.
